Sandra Jernström holds a PhD in cancer genetics from the University of Oslo, where she together with her colleagues integrated different omics data from a breast cancer cohort to better stratify the patients. She has expertise in high-throughput drug and siRNA screening of 2D and 3D cell culture models, where she explored the difference in drug resistance mechanisms seen between the culture models. Before joining Okomera, she worked as a postdoc at Karolinska Institute in Sweden, with the aim to develop a method to perform drug screening directly on patient biopsies in 3D, to be able to guide the treatment. For this project she won a significant research grant competition at the SLUSH conference in Finland in 2018. In 2020, she joined Okomera, where she leads the bio application team and is in charge of clinical partnerships to gain clinical validation of the technology.
Clinical Dx Showcase:
Okomera has developed a technology for screening cancer biopsies in order to select the best treatment for each patient.
Precision Cancer Medicine on a chip
Functional screening for drug efficacy assessment using 3D microtumors derived from cancer biopsies.
The PMWC 2023 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.